Company Filing History:
Years Active: 2009
Title: Holger Ulbrich: Innovator in Selectin Inhibition
Introduction
Holger Ulbrich is a notable inventor based in Mainz, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel inhibitors for selectins. His work focuses on creating effective treatments for inflammatory diseases.
Latest Patents
Holger Ulbrich holds 1 patent for his invention titled "Non-glycosidic and non-peptidic inhibitors of selectin, and the use thereof." This patent describes a new class of low molecular weight inhibitors that are non-toxic and effective in vivo. These compounds offer advantages over traditional glycosidic inhibitors, demonstrating greater potency in vitro compared to the known drug bimosiamose. The patent also outlines methods for the production of these compounds and their applications in treating various diseases.
Career Highlights
Holger Ulbrich is affiliated with Johannes Gutenberg-Universität Mainz, where he conducts research and develops innovative solutions in the field of pharmacology. His work has garnered attention for its potential to improve therapeutic options for patients suffering from inflammatory conditions.
Collaborations
Holger has collaborated with esteemed colleagues such as Gerd Dannhardt and Philip Prech. Their combined expertise has contributed to advancing research in selectin inhibition and related therapeutic areas.
Conclusion
Holger Ulbrich's contributions to the field of medicinal chemistry, particularly through his innovative patent on selectin inhibitors, highlight his role as a key figure in developing new therapeutic strategies. His work continues to pave the way for advancements in treating inflammatory diseases.